ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

WHWK vs ADCT // EV/EBITDA & P/E VALUATION

Whitehawk Therapeutics Inc. (NASDAQ) VS. ADC Therapeutics SA (NYSE) • 15-METRIC TALLY: WHWK 0 — ADCT 5
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WHWK VS. ADCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC WHWK ADCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 89.40% 92.90% -3.50 ADCT /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 14.90% -79.90 ADCT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 3.11 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 ADCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.9 53.9 -11.02 ADCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $188.1M $190.2M -$2.1M ADCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR WHWK REV ADCT REV WHWK GROSS % ADCT GROSS % WHWK FCF ADCT FCF
FY 2025 $7.1M $81.4M 89.4% 92.9% -$98.0M -$141.4M
FY 2024 $26.0M $70.8M 88.4% 91.6% -$61.2M -$124.7M
FY 2023 $24.4M $69.1M — — -$59.7M -$118.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WHWK // BETA —
ADCT // BETA —